RESUMO
Objectives: Lung adenocarcinoma (LUAD) is the most common newly diagnosed malignant tumor in older people. As older patients age, organ function decreases, leading to increased adverse reactions to treatment. The epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase tyrosine (ALK) tyrosine kinase inhibitors (TKIs) therapy are more effective and well-tolerated than chemotherapy, while the rate of genetic testing and subsequent targeted treatment among older patients remains relatively low, the clinical benefit limitation for those patients. This study aims to investigate the mutation characteristics of LUAD diver gene and its relationship with clinicopathological features in older LUAD. Materials and methods: A total of 275 patients were diagnosed as LUAD and were over sixty years old. We utilized next-generation sequencing technology to detect and analyze gene mutations in postoperative tissue specimens, including EGFR, KRAS, ALK, ROS1, RET, MET, BRAF, HER2, PIK3CA and NRAS. Results: A total of 90.18% (248/275) of older LUAD patients experienced genetic mutations. The EGFR (192, 69.82%) had the highest mutation rate among ten genes, followed by KRAS (21, 7.64%), MET (21, 7.64%), ERBB2 (15, 5.45%), RET (9, 3.27%), ALK (8, 2.91%), ROS1 (8, 2.91%), PIK3CA (6, 2.18%), BRAF (5, 1.82%) and NRAS (1, 0.36%). We also found thirty patients (15.63%) with EGFR mutations also having other gene mutations. The L858R mutation and exon19 deletion were the predominant EGFR mutations, accounting for 84.90% of EGFR-mutated patients. In addition, fifty-one kinds of EGFR mutations were detected, distributed in the protein tyrosine kinase catalytic domain (43, 84.31%), cysteine enriched domain (4, 7.84%), receptor binding domain (3, 5.88%), and EGFR transmembrane domain (1,1.96%). Ten cases of gene fusion mutation were detected. Two rare partner genes, PKHD1 (P60:R34) and STK39 (R33:S11), were detected by ROS1 gene fusion. RET gene fusion revealed a rare companion gene KCND2 (R11:K2). The EGFR mutations were more prevalent in female, non-smoking patients (p < 0.05), and the KRAS mutations were more common in male and smoking patients (p < 0.01). In addition, the BRAF mutations were more likely to occur in the right lung (p < 0.05). Conclusion: Older LUAD populations exhibit diverse genetic mutations, which may also exist simultaneously. Simultaneous detection of multiple genes by NGS can accelerate and enhance targeted treatment benefits for older LUAD patients, ultimately improving their quality of life.
RESUMO
In this work, we used a cross-sectional study to evaluate influence of menarche age, menstrual cycle, menstrual period, menopausal age, and menopause years for osteoporosis in women from China. We found that different menarche age, menstrual cycle, menopausal years, and menopausal age are related with the prevalence of osteoporosis. However, menarche age exceeds 17 years and menopausal age smaller than 48 years are risk factors for osteoporosis in women. STUDY DESIGN: A cross-sectional, population-based study. PURPOSE: The purpose of this study was to explore relationship between prevalence of osteoporosis and menarche age, menstrual cycle, menstrual period, menopausal age, and menopause years for women. METHODS: From March to October 2016, the cluster sampling method was used to conduct an osteoporosis-related questionnaire survey on women aged 40-80 in two communities in Lanzhou City, Gansu, China, and bone mineral density(BMD)was carried out using the DTX-200 dual-energy X-ray absorptiometer produced by the US OSTEOMETER company. The relationship between prevalence of osteoporosis and menarche age, menstrual cycle, menstrual period, menopausal age, and menopause years were analyzed using logistic regression analysis. RESULTS: There were 2224 female participates enrolled in this study and average age was 61.60 ± 8.05 years and total rate of prevalence was 32.73%; among them, different menarche age, menstrual cycle, menopausal years, and menopausal age have statistical differences with the prevalence of osteoporosis, but there is no statistical difference between different menstruation and the prevalence of osteoporosis. Single logistic regression analysis found that older menarche age, earlier menopausal age, and longer menopausal years were related factors for the prevalence of osteoporosis, while menarche age exceed 17 years and menopausal age smaller than 48 years are risk factors for osteoporosis for women in multivariate regression analysis. CONCLUSIONS: In China, ages at menarche and menopause are associated with prevalence of osteoporosis. Later, menarche and earlier menopause are associated with higher osteoporosis risk. Menarche and menopause history may help identify women with increased risk of developing osteoporosis.
